Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 207

1.

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.

Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de Sa Carvalho B, Chagas VS, Mungall KL, Sadeghi S, Pedamallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ; TCGA Research Network, Weinstein JN, Kwiatkowski DJ, Lerner SP.

Cell. 2018 Aug 9;174(4):1033. doi: 10.1016/j.cell.2018.07.036. No abstract available.

PMID:
30096301
2.

Targeted Suppression and Knockout of ASCT2 or LAT1 in Epithelial and Mesenchymal Human Liver Cancer Cells Fail to Inhibit Growth.

Bothwell PJ, Kron CD, Wittke EF, Czerniak BN, Bode BP.

Int J Mol Sci. 2018 Jul 19;19(7). pii: E2093. doi: 10.3390/ijms19072093.

3.

Urine cell-based DNA methylation classifier for monitoring bladder cancer.

van der Heijden AG, Mengual L, Ingelmo-Torres M, Lozano JJ, van Rijt-van de Westerlo CCM, Baixauli M, Geavlete B, Moldoveanud C, Ene C, Dinney CP, Czerniak B, Schalken JA, Kiemeney LALM, Ribal MJ, Witjes JA, Alcaraz A.

Clin Epigenetics. 2018 May 30;10:71. doi: 10.1186/s13148-018-0496-x. eCollection 2018.

4.

Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases.

Wang G, Xiao L, Zhang M, Kamat AM, Siefker-Radtke A, Dinney CP, Czerniak B, Guo CC.

Hum Pathol. 2018 Sep;79:57-65. doi: 10.1016/j.humpath.2018.05.005. Epub 2018 May 12.

PMID:
29763719
5.

Biomarkers could facilitate prediction of worse clinical outcome of cancer with special insight to cervical cancer.

Czerniak B, Olszewska-Słonina D.

Contemp Oncol (Pozn). 2018;22(1):1-7. doi: 10.5114/wo.2018.74386. Epub 2018 Apr 3. Review.

6.

Detection of Bladder Cancer in Urine Sediments by a Novel Multicolor Fluorescence In Situ Hybridization (Quartet) Test.

Zhang S, Wang Y, Bondaruk J, Majewski T, Yao H, Lee S, Lee JG, Cogdell D, Lotan Y, Dinney C, Wei P, Baggerly K, Czerniak B.

Eur Urol Focus. 2018 Feb 7. pii: S2405-4569(18)30018-X. doi: 10.1016/j.euf.2018.01.017. [Epub ahead of print]

PMID:
29428551
7.

Body mass index as a biomarker for the evaluation of the "Obesity Paradox" among inpatients.

Tojek K, Wustrau B, Czerniak B, Korzycka-Wilińska W, Winiarski P, Banaszkiewicz Z, Budzyński J.

Clin Nutr. 2017 Dec 20. pii: S0261-5614(17)31425-5. doi: 10.1016/j.clnu.2017.12.005. [Epub ahead of print]

PMID:
29291899
8.

Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer.

Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, Hinoue T, Laird PW, Hoadley KA, Akbani R, Castro MAA, Gibb EA, Kanchi RS, Gordenin DA, Shukla SA, Sanchez-Vega F, Hansel DE, Czerniak BA, Reuter VE, Su X, de Sa Carvalho B, Chagas VS, Mungall KL, Sadeghi S, Pedamallu CS, Lu Y, Klimczak LJ, Zhang J, Choo C, Ojesina AI, Bullman S, Leraas KM, Lichtenberg TM, Wu CJ, Schultz N, Getz G, Meyerson M, Mills GB, McConkey DJ; TCGA Research Network, Weinstein JN, Kwiatkowski DJ, Lerner SP.

Cell. 2017 Oct 19;171(3):540-556.e25. doi: 10.1016/j.cell.2017.09.007. Epub 2017 Oct 5. Erratum in: Cell. 2018 Aug 9;174(4):1033.

9.

Carcinoma of the urethra.

Zhang M, Adeniran AJ, Vikram R, Tamboli P, Pettaway C, Bondaruk J, Liu J, Baggerly K, Czerniak B.

Hum Pathol. 2018 Feb;72:35-44. doi: 10.1016/j.humpath.2017.08.006. Epub 2017 Aug 18.

PMID:
28827100
10.

High-grade neuroendocrine carcinoma of the urachus-report of 3 cases.

Wang G, Huang H, Kamat AM, Siefker-Radtke A, Dinney CP, Troncoso P, Czerniak B, Guo CC.

Hum Pathol. 2017 Sep;67:126-133. doi: 10.1016/j.humpath.2017.08.003. Epub 2017 Aug 18.

PMID:
28823575
11.

Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion.

Metcalfe MJ, Ferguson JE, Li R, Xiao L, Guo CC, Czerniak BA, Siefker-Radtke A, Pretzsch SM, Navai N, McConkey DJ, Kamat AM, Campbell M, Dinney C.

Eur Urol Focus. 2017 Dec;3(6):577-583. doi: 10.1016/j.euf.2017.06.004. Epub 2017 Jul 13.

12.

[S100A4 , MACC - 1 , REG - 4 - promising biomarkers of metastasis in cancers].

Czerniak B, Olszewska-Słonina D, Cwynar A.

Wiad Lek. 2017;70(3 pt 2):604-607. Polish.

PMID:
28713091
13.

Sarcomatoid Renal Cell Carcinoma Has a Distinct Molecular Pathogenesis, Driver Mutation Profile, and Transcriptional Landscape.

Wang Z, Kim TB, Peng B, Karam J, Creighton C, Joon A, Kawakami F, Trevisan P, Jonasch E, Chow CW, Canales JR, Tamboli P, Tannir N, Wood C, Monzon F, Baggerly K, Varella-Garcia M, Czerniak B, Wistuba I, Mills G, Shaw K, Chen K, Sircar K.

Clin Cancer Res. 2017 Nov 1;23(21):6686-6696. doi: 10.1158/1078-0432.CCR-17-1057. Epub 2017 Jul 14.

14.

Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.

Moss TJ, Qi Y, Xi L, Peng B, Kim TB, Ezzedine NE, Mosqueda ME, Guo CC, Czerniak BA, Ittmann M, Wheeler DA, Lerner SP, Matin SF.

Eur Urol. 2017 Oct;72(4):641-649. doi: 10.1016/j.eururo.2017.05.048. Epub 2017 Jun 7.

PMID:
28601352
15.

Primary Ewing Sarcoma / Primitive Neuroectodermal Tumor of the Kidney: A Clinicopathologic Study of 23 Cases.

Murugan P, Rao P, Tamboli P, Czerniak B, Guo CC.

Pathol Oncol Res. 2018 Jan;24(1):153-159. doi: 10.1007/s12253-017-0228-0. Epub 2017 Apr 20.

PMID:
28429277
16.

Plasmacytoid Urothelial Carcinoma of the Urinary Bladder: A Clinicopathologic and Immunohistochemical Analysis of 49 Cases.

Fox MD, Xiao L, Zhang M, Kamat AM, Siefker-Radtke A, Zhang L, Dinney CP, Czerniak B, Guo CC.

Am J Clin Pathol. 2017 May 1;147(5):500-506. doi: 10.1093/ajcp/aqx029.

PMID:
28371875
17.

Aurora Kinase A is a Biomarker for Bladder Cancer Detection and Contributes to its Aggressive Behavior.

Mobley A, Zhang S, Bondaruk J, Wang Y, Majewski T, Caraway NP, Huang L, Shoshan E, Velazquez-Torres G, Nitti G, Lee S, Lee JG, Fuentes-Mattei E, Willis D, Zhang L, Guo CC, Yao H, Baggerly K, Lotan Y, Lerner SP, Dinney C, McConkey D, Bar-Eli M, Czerniak B.

Sci Rep. 2017 Jan 19;7:40714. doi: 10.1038/srep40714.

18.

Functional CAR models for large spatially correlated functional datasets.

Zhang L, Baladandayuthapani V, Zhu H, Baggerly KA, Majewski T, Czerniak BA, Morris JS.

J Am Stat Assoc. 2016;111(514):772-786. doi: 10.1080/01621459.2015.1042581. Epub 2016 Aug 18.

19.

Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer.

Ochoa AE, Choi W, Su X, Siefker-Radtke A, Czerniak B, Dinney C, McConkey DJ.

Oncotarget. 2016 Dec 6;7(49):80164-80174. doi: 10.18632/oncotarget.13284.

20.

Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use.

Dadhania V, Zhang M, Zhang L, Bondaruk J, Majewski T, Siefker-Radtke A, Guo CC, Dinney C, Cogdell DE, Zhang S, Lee S, Lee JG, Weinstein JN, Baggerly K, McConkey D, Czerniak B.

EBioMedicine. 2016 Oct;12:105-117. doi: 10.1016/j.ebiom.2016.08.036. Epub 2016 Aug 25.

21.

Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer.

Fernández MI, Williams SB, Willis DL, Slack RS, Dickstein RJ, Parikh S, Chiong E, Siefker-Radtke AO, Guo CC, Czerniak BA, McConkey DJ, Shah JB, Pisters LL, Grossman HB, Dinney CP, Kamat AM.

BJU Int. 2017 May;119(5):684-691. doi: 10.1111/bju.13689. Epub 2016 Nov 11.

22.

RGS6 is an essential tumor suppressor that prevents bladder carcinogenesis by promoting p53 activation and DNMT1 downregulation.

Yang J, Platt LT, Maity B, Ahlers KE, Luo Z, Lin Z, Chakravarti B, Ibeawuchi SR, Askeland RW, Bondaruk J, Czerniak BA, Fisher RA.

Oncotarget. 2016 Oct 25;7(43):69159-69172. doi: 10.18632/oncotarget.12473.

23.

Biphasic components of sarcomatoid clear cell renal cell carcinomas are molecularly similar to each other, but distinct from, non-sarcomatoid renal carcinomas.

Sircar K, Yoo SY, Majewski T, Wani K, Patel LR, Voicu H, Torres-Garcia W, Verhaak RG, Tannir N, Karam JA, Jonasch E, Wood CG, Tamboli P, Baggerly KA, Aldape KD, Czerniak B.

J Pathol Clin Res. 2015 Jul 7;1(4):212-24. doi: 10.1002/cjp2.23. eCollection 2015 Oct.

24.

Comparison between whole mount tissue preparations and virtual tissue microarray samples for measuring Ki-67 and apoptosis indices in human bladder cancer: A cross-sectional study.

Oshiro H, Czerniak BA, Sakamaki K, Tsuta K, Bondaruk J, Keyhani A, Dinney CP, Nagai T, Kamat AM.

Medicine (Baltimore). 2016 Aug;95(31):e4500. doi: 10.1097/MD.0000000000004500.

25.

Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasis.

Roth B, Jayaratna I, Sundi D, Cheng T, Melquist J, Choi W, Porten S, Nitti G, Navai N, Wszolek M, Guo C, Czerniak B, McConkey D, Dinney C.

Oncotarget. 2017 May 23;8(21):34205-34222. doi: 10.18632/oncotarget.11009.

26.

Next-generation sequencing identifies high frequency of mutations in potentially clinically actionable genes in sebaceous carcinoma.

Tetzlaff MT, Singh RR, Seviour EG, Curry JL, Hudgens CW, Bell D, Wimmer DA, Ning J, Czerniak BA, Zhang L, Davies MA, Prieto VG, Broaddus RR, Ram P, Luthra R, Esmaeli B.

J Pathol. 2016 Sep;240(1):84-95. doi: 10.1002/path.4759.

PMID:
27287813
27.

Scores of nutritional risk and parameters of nutritional status assessment as predictors of in-hospital mortality and readmissions in the general hospital population.

Budzyński J, Tojek K, Czerniak B, Banaszkiewicz Z.

Clin Nutr. 2016 Dec;35(6):1464-1471. doi: 10.1016/j.clnu.2016.03.025. Epub 2016 Apr 4.

PMID:
27113120
28.

Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer.

Guo CC, Dadhania V, Zhang L, Majewski T, Bondaruk J, Sykulski M, Wronowska W, Gambin A, Wang Y, Zhang S, Fuentes-Mattei E, Kamat AM, Dinney C, Siefker-Radtke A, Choi W, Baggerly KA, McConkey D, Weinstein JN, Czerniak B.

Eur Urol. 2016 Oct;70(4):611-620. doi: 10.1016/j.eururo.2016.02.056. Epub 2016 Mar 15.

29.

Long non-coding RNA containing ultraconserved genomic region 8 promotes bladder cancer tumorigenesis.

Olivieri M, Ferro M, Terreri S, Durso M, Romanelli A, Avitabile C, De Cobelli O, Messere A, Bruzzese D, Vannini I, Marinelli L, Novellino E, Zhang W, Incoronato M, Ilardi G, Staibano S, Marra L, Franco R, Perdonà S, Terracciano D, Czerniak B, Liguori GL, Colonna V, Fabbri M, Febbraio F, Calin GA, Cimmino A.

Oncotarget. 2016 Apr 12;7(15):20636-54. doi: 10.18632/oncotarget.7833.

30.

Origins of Bladder Cancer.

Czerniak B, Dinney C, McConkey D.

Annu Rev Pathol. 2016 May 23;11:149-74. doi: 10.1146/annurev-pathol-012513-104703. Epub 2016 Feb 22. Review.

PMID:
26907529
31.

Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma.

Cancer Genome Atlas Research Network, Linehan WM, Spellman PT, Ricketts CJ, Creighton CJ, Fei SS, Davis C, Wheeler DA, Murray BA, Schmidt L, Vocke CD, Peto M, Al Mamun AA, Shinbrot E, Sethi A, Brooks S, Rathmell WK, Brooks AN, Hoadley KA, Robertson AG, Brooks D, Bowlby R, Sadeghi S, Shen H, Weisenberger DJ, Bootwalla M, Baylin SB, Laird PW, Cherniack AD, Saksena G, Haake S, Li J, Liang H, Lu Y, Mills GB, Akbani R, Leiserson MD, Raphael BJ, Anur P, Bottaro D, Albiges L, Barnabas N, Choueiri TK, Czerniak B, Godwin AK, Hakimi AA, Ho TH, Hsieh J, Ittmann M, Kim WY, Krishnan B, Merino MJ, Mills Shaw KR, Reuter VE, Reznik E, Shelley CS, Shuch B, Signoretti S, Srinivasan R, Tamboli P, Thomas G, Tickoo S, Burnett K, Crain D, Gardner J, Lau K, Mallery D, Morris S, Paulauskis JD, Penny RJ, Shelton C, Shelton WT, Sherman M, Thompson E, Yena P, Avedon MT, Bowen J, Gastier-Foster JM, Gerken M, Leraas KM, Lichtenberg TM, Ramirez NC, Santos T, Wise L, Zmuda E, Demchok JA, Felau I, Hutter CM, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Zhang J, Ayala B, Baboud J, Chudamani S, Liu J, Lolla L, Naresh R, Pihl T, Sun Q, Wan Y, Wu Y, Ally A, Balasundaram M, Balu S, Beroukhim R, Bodenheimer T, Buhay C, Butterfield YS, Carlsen R, Carter SL, Chao H, Chuah E, Clarke A, Covington KR, Dahdouli M, Dewal N, Dhalla N, Doddapaneni HV, Drummond JA, Gabriel SB, Gibbs RA, Guin R, Hale W, Hawes A, Hayes DN, Holt RA, Hoyle AP, Jefferys SR, Jones SJ, Jones CD, Kalra D, Kovar C, Lewis L, Li J, Ma Y, Marra MA, Mayo M, Meng S, Meyerson M, Mieczkowski PA, Moore RA, Morton D, Mose LE, Mungall AJ, Muzny D, Parker JS, Perou CM, Roach J, Schein JE, Schumacher SE, Shi Y, Simons JV, Sipahimalani P, Skelly T, Soloway MG, Sougnez C, Tam A, Tan D, Thiessen N, Veluvolu U, Wang M, Wilkerson MD, Wong T, Wu J, Xi L, Zhou J, Bedford J, Chen F, Fu Y, Gerstein M, Haussler D, Kasaian K, Lai P, Ling S, Radenbaugh A, Van Den Berg D, Weinstein JN, Zhu J, Albert M, Alexopoulou I, Andersen JJ, Auman JT, Bartlett J, Bastacky S, Bergsten J, Blute ML, Boice L, Bollag RJ, Boyd J, Castle E, Chen YB, Cheville JC, Curley E, Davies B, DeVolk A, Dhir R, Dike L, Eckman J, Engel J, Harr J, Hrebinko R, Huang M, Huelsenbeck-Dill L, Iacocca M, Jacobs B, Lobis M, Maranchie JK, McMeekin S, Myers J, Nelson J, Parfitt J, Parwani A, Petrelli N, Rabeno B, Roy S, Salner AL, Slaton J, Stanton M, Thompson RH, Thorne L, Tucker K, Weinberger PM, Winemiller C, Zach LA, Zuna R.

N Engl J Med. 2016 Jan 14;374(2):135-45. doi: 10.1056/NEJMoa1505917. Epub 2015 Nov 4.

32.

Evaluation of the efficiency of hospital antibiotic policy applied Dr Jan Biziel University Hospital No 2 in Bydgoszcz in 2009-2013.

Kuziemski A, Frankowska K, Gonia E, Czerniak B, Bakhurynska O, Sobociński Z.

Przegl Epidemiol. 2015;69(3):523-8, 633-6. English, Polish.

33.

Urachal carcinoma: a pathologic and clinical study of 46 cases.

Dhillon J, Liang Y, Kamat AM, Siefker-Radtke A, Dinney CP, Czerniak B, Guo CC.

Hum Pathol. 2015 Dec;46(12):1808-14. doi: 10.1016/j.humpath.2015.07.021. Epub 2015 Aug 12.

34.

A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer.

McConkey DJ, Choi W, Shen Y, Lee IL, Porten S, Matin SF, Kamat AM, Corn P, Millikan RE, Dinney C, Czerniak B, Siefker-Radtke AO.

Eur Urol. 2016 May;69(5):855-62. doi: 10.1016/j.eururo.2015.08.034. Epub 2015 Sep 3.

35.

Adenocarcinoma of the urinary bladder.

Dadhania V, Czerniak B, Guo CC.

Am J Clin Exp Urol. 2015 Aug 8;3(2):51-63. eCollection 2015. Review.

36.

Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.

Varkaris A, Corn PG, Parikh NU, Efstathiou E, Song JH, Lee YC, Aparicio A, Hoang AG, Gaur S, Thorpe L, Maity SN, Bar Eli M, Czerniak BA, Shao Y, Alauddin M, Lin SH, Logothetis CJ, Gallick GE.

Clin Cancer Res. 2016 Jan 1;22(1):107-21. doi: 10.1158/1078-0432.CCR-15-0235. Epub 2015 Aug 13.

37.

Intratumoral morphologic and molecular heterogeneity of rhabdoid renal cell carcinoma: challenges for personalized therapy.

Singh RR, Murugan P, Patel LR, Voicu H, Yoo SY, Majewski T, Mehrotra M, Wani K, Tannir N, Karam JA, Jonasch E, Wood CG, Creighton CJ, Medeiros LJ, Broaddus RR, Tamboli P, Baggerly KA, Aldape KD, Czerniak B, Luthra R, Sircar K.

Mod Pathol. 2015 Sep;28(9):1225-35. doi: 10.1038/modpathol.2015.68. Epub 2015 Jun 26.

38.

Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer.

McConkey DJ, Choi W, Ochoa A, Siefker-Radtke A, Czerniak B, Dinney CP.

Hematol Oncol Clin North Am. 2015 Apr;29(2):377-94, x-xi. doi: 10.1016/j.hoc.2014.11.003. Review.

PMID:
25836941
39.

Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum.

Dinney CP, Hansel D, McConkey D, Shipley W, Hagan M, Dreicer R, Lerner S, Czerniak B, Waldman F, Groshen S, True LD, Petricoin E, Theodorescu D, Hruszkewycz A, Bajorin D.

Urol Oncol. 2014 Nov;32(8):1108-15. doi: 10.1016/j.urolonc.2013.10.021. Epub 2014 Oct 24. Review.

40.

Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants.

Li W, Liang Y, Deavers MT, Kamat AM, Matin SF, Dinney CP, Czerniak B, Guo CC.

Am J Clin Pathol. 2014 Dec;142(6):864-71. doi: 10.1309/AJCP1J0JPJBPSUXF.

PMID:
25389341
41.

Clinical outcomes of cT1 micropapillary bladder cancer.

Willis DL, Fernandez MI, Dickstein RJ, Parikh S, Shah JB, Pisters LL, Guo CC, Henderson S, Czerniak BA, Grossman HB, Dinney CP, Kamat AM.

J Urol. 2015 Apr;193(4):1129-34. doi: 10.1016/j.juro.2014.09.092. Epub 2014 Sep 22.

42.

Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward.

Apolo AB, Hoffman V, Kaag MG, Latini DM, Lee CT, Rosenberg JE, Knowles M, Theodorescu D, Czerniak BA, Efstathiou JA, Albert ML, Sridhar SS, Margulis V, Matin SF, Galsky MD, Hansel D, Kamat AM, Flaig TW, Smith AB, Messing E, Zipursky Quale D, Lotan Y.

Urol Oncol. 2015 Feb;33(2):53-64. doi: 10.1016/j.urolonc.2014.06.013. Epub 2014 Jul 25. Review.

PMID:
25065704
43.

Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.

Choi W, Czerniak B, Ochoa A, Su X, Siefker-Radtke A, Dinney C, McConkey DJ.

Nat Rev Urol. 2014 Jul;11(7):400-10. doi: 10.1038/nrurol.2014.129. Epub 2014 Jun 24. Review.

PMID:
24960601
44.

Differential expression of GATA-3 in urothelial carcinoma variants.

Liang Y, Heitzman J, Kamat AM, Dinney CP, Czerniak B, Guo CC.

Hum Pathol. 2014 Jul;45(7):1466-72. doi: 10.1016/j.humpath.2014.02.023. Epub 2014 Mar 15.

PMID:
24745616
45.

Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.

Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K, Siefker-Radtke A, Czerniak B, Dinney CP, McConkey DJ.

Cancer Cell. 2014 Feb 10;25(2):152-65. doi: 10.1016/j.ccr.2014.01.009.

46.

Frequent truncating mutations of STAG2 in bladder cancer.

Solomon DA, Kim JS, Bondaruk J, Shariat SF, Wang ZF, Elkahloun AG, Ozawa T, Gerard J, Zhuang D, Zhang S, Navai N, Siefker-Radtke A, Phillips JJ, Robinson BD, Rubin MA, Volkmer B, Hautmann R, Küfer R, Hogendoorn PC, Netto G, Theodorescu D, James CD, Czerniak B, Miettinen M, Waldman T.

Nat Genet. 2013 Dec;45(12):1428-30. doi: 10.1038/ng.2800. Epub 2013 Oct 13.

47.

Urothelial tumors of the urinary bladder in young patients: a clinicopathologic study of 59 cases.

Stanton ML, Xiao L, Czerniak BA, Guo CC.

Arch Pathol Lab Med. 2013 Oct;137(10):1337-41. doi: 10.5858/arpa.2012-0322-OA.

48.

HINCUTs in cancer: hypoxia-induced noncoding ultraconserved transcripts.

Ferdin J, Nishida N, Wu X, Nicoloso MS, Shah MY, Devlin C, Ling H, Shimizu M, Kumar K, Cortez MA, Ferracin M, Bi Y, Yang D, Czerniak B, Zhang W, Schmittgen TD, Voorhoeve MP, Reginato MJ, Negrini M, Davuluri RV, Kunej T, Ivan M, Calin GA.

Cell Death Differ. 2013 Dec;20(12):1675-87. doi: 10.1038/cdd.2013.119. Epub 2013 Sep 13.

49.

Refining patient selection for neoadjuvant chemotherapy before radical cystectomy.

Culp SH, Dickstein RJ, Grossman HB, Pretzsch SM, Porten S, Daneshmand S, Cai J, Groshen S, Siefker-Radtke A, Millikan RE, Czerniak B, Navai N, Wszolek MF, Kamat AM, Dinney CP.

J Urol. 2014 Jan;191(1):40-7. doi: 10.1016/j.juro.2013.07.061. Epub 2013 Jul 30.

50.

Relationship between primary and metastatic testicular germ cell tumors: a clinicopathologic analysis of 100 cases.

Tarrant WP, Czerniak BA, Guo CC.

Hum Pathol. 2013 Oct;44(10):2220-6. doi: 10.1016/j.humpath.2013.05.004. Epub 2013 Jul 12.

PMID:
23856516

Supplemental Content

Loading ...
Support Center